Although the proteasome inhibitor bortezomib (BTZ) shows excellent efficacy in multiple myeloma (MM), a fraction of patients has a suboptimal or no response to this agent. In addition, BTZ-induced peripheral neuropathy (BiPN), a frequent side-effect of this therapy, limits its use in some patients. This study aimed to explore serum lipid biomarker candidates to predict the response to BTZ and the severity of BiPN.
| INTRODUC TI ON
The proteasome inhibitor bortezomib (BTZ) is widely used in the treatment of multiple myeloma (MM). This agent strongly inhibits proteasome activity, which results in homeostasis disruption between protein synthesis and destruction. Bortezomib treatment often yields excellent responses, both partial response (PR) and complete response (CR), not only in newly diagnosed MM, but also in patients who have relapsed or are refractory to other treatment.
However, not all patients treated with this agent experience such a favorable outcome. Suboptimal or no responses to BTZ are seen in a fraction of patients, and the efficacy of the agent is unpredictable.
In addition, BTZ-induced peripheral neuropathy (BiPN), an accompanying neuropathic pain and reflex suppression, is a frequent side effect of the therapy. Bortezomib-induced peripheral neuropathy is thought to occur at a certain treatment threshold (within 5 cycles, but rarely beyond) in 40%-60% of patients, of whom 15%-40% will develop severe peripheral neuropathy (grade 2 or higher). [1] [2] [3] [4] [5] As no effective prophylactic treatment is available, the onset of BiPN limits the use of BTZ in some patients. Therefore, identifying patients who have a potential drug resistance or high risk of developing BiPN is an important issue.
To date, a few potential biomarkers associated with the efficacy and toxicity of BTZ treatment have been proposed. A genome-wide association study identified that genetic polymorphisms of PKNOX1 (transcription factor PBX/knotted 1 homeobox 1) and those in the immediate vicinity of CBS (cystathionine-β-synthetase) were associated with severe BTZ-induced toxicity. 6 Comparative proteomic profiling of sera from patients with refractory MM revealed 54 proteins that differentiated each analyzed experimental group, dividing them based on their response to therapy. 7 Zaal et al 8 aimed to identify the altered metabolic pathways that drove resistance in BTZ-resistant MM cells. As a result, they indicated that interfering with the serine metabolism could be a novel strategy to improve BTZ therapy, and identified 3-phosphoglycerate dehydrogenase, the rate-limiting enzyme of serine synthesis, as a potential biomarker for BTZ resistance.
Metabolomics is a powerful approach for exploring diagnostic biomarkers and druggable targets, because endogenous metabolites are responsible for phenotypic manifestations as a final expression of genomic information. Lipidomics, a lipid-targeting subarea of metabolomics, is an especially promising approach to biomarker discovery, because lipids are important players in a variety of complex physiological processes, executing important functions by acting as cellular membrane components, signaling mediators, energy reserve molecules, and endocrine regulators.
We have already established global lipidomic analytical systems using liquid chromatography (LC)-time-of-flight mass spectrometry (TOFMS), or triple quadrupole mass spectrometry (MS/MS) to measure lipid (eg, phospholipids) metabolites in biological samples. 9 Applying this system to the study of disease metabolomics using clinical samples, the lipidomic signatures of clear cell renal cell carcinoma were obtained to reveal the metabolic changes in cancerous tissue and renal cell carcinoma pathophysiology. 10 In this study, we undertook a lipid metabolomics analysis of pretreatment sera from patients with MM who received BTZ plus low-dose dexamethasone (Bd) therapy, to identify predictive response markers for Bd therapy and BiPN severity.
| MATERIAL S AND ME THODS

| Clinical serum specimens
A total of 59 patients with MM were recruited between October 2007 and December 2014 at the Nagoya City University Hospital (Nagoya, Japan). Their venous blood was collected before Bd therapy in the morning after 14 hours fasting. Samples were centrifuged according to the manufacturer's instructions, and the serum was separated within 2 hours after blood sample collection. Patients were diagnosed according to the International Myeloma Working Group uniform response criteria 11 and divided into 6 response subcategories: CR, very good partial response (VGPR), PR, minor response (MR), stable disease (SD), and progressive disease (PD).
The BiPN grades (grades 0-3) of the study subjects were diagnosed according to CTCAE version 4.0. The patient characteristics are summarized in Table 1 , and their details are shown in Table S1 . The 
| Metabolomic analysis of clinical serum samples
Detailed information regarding the extraction and measurement of lipid metabolites was described in our previous paper. 12 Briefly, lipid metabolites were extracted from 100 μL serum using the method described by Bligh and Dyer (BD), 13 XL; Thermo Fisher Scientific) as previously described. 12 The UPLC-TOFMS data were processed using the 2DICAL software (Mitsui Knowledge Industry), and the extracted ion peak heights were normalized using IS. The data for PUFAs and oxFAs from the UPLC-MS/MS were processed using MultiQuant software version 2.1 (AB Sciex), and the integrated peak area of each metabolite was normalized to IS.
| Statistical and multiple classification analyses
The lipid metabolite levels were relatively quantified as the ion count ratio of each metabolite to the internal standard. Statistical analyses were carried out using the Jonckheere-Terpstra trend test to examine ordered differences in metabolite levels for the 3 response subcategories (PD + SD, PR + MR, and CR + VGPR) or the 4 BiPN grades (G0, G1, G2, and G3). The R statistical environment (http://r-proje ct.org/) software was used for the statistical analyses. Differences with P values <.005 were considered significant in accordance with the recent proposal on P value threshold for statistical significance by Benjamin et al. 14 The multiple testing correction was not applied, as metabolite levels are not exclusive but rather related to each other, and we focused on revealing the contributions of overall metabolic changes (such as pathways or metabolite groups) to the responses to Bd therapy in the serum of MM patients. Differences in the distribution of patient background characteristics between the analytical groups were assessed by the χ 2 test or Fisher's exact test and the Mann-Whitney U test for categorical and continuous variables, respectively. Differences with P values <.005 were considered statistically significant. 14 
| RE SULTS
| Distribution of patient background characteristics
We first evaluated whether the patients' background characteristics were differently associated with the response to Bd therapy and BiPN severity. Concerning efficacy, there were no significant differences (P < .005) in background characteristics between responders (CR, VGPR, PR, and MR) and nonresponders (SD and PD), although both body mass index (BMI) (P = .0296) and serum albumin (P = .0095) tended to be higher in responders than in nonresponders (Table S2) . For BiPN severity, the presence or absence of prior (Table S3 ).
| Profiling of lipid metabolites measured by UPLC-TOFMS and UPLC-MS/MS
In total, 385 detected lipids were classified into 4 classes (120 GPLs, 49 SLs, 177 NLs, and 39 oxFAs), which were further divided into 20
subclasses (Table S4 ). The relative quantification levels of the GPLs, SLs, and NLs for each patient are shown in Table S5 , and those of the FAs in Table S6 .
| Lipid metabolites associated with response to Bd therapy
First, to identify the lipid metabolites associated with the response to Bd therapy, their serum levels were statistically compared among the 3 response groups (CR + VGPR, PR + MR, and SD + PD) (Table S7) (Table S8) , none of the metabolites showed significantly different levels between nonresponders, minor/partial responders, and good responders.
| Lipid metabolites associated with severity of BiPN
Next, the association of lipid metabolite levels with the peripheral neuropathy grades was examined (Tables S7 and S8 ). When the levels of each metabolite were compared between the groups of patients with the 4 ordered BiPN grades (G0-G3), 14 metabolites showed significantly different levels (Table 3) . They comprised 1 ether-type lysophosphatidylcholine (LPC), 1 PC, 1 ceramide, 1 diacylglycerol, 1 triacylglycerol, and 9 oxFAs. Their levels were increased progressively in patients with BiPN grades from G0 to G3, except for 8,9-diHETrE levels, which were decreased over the BiPN grades.
The median fold change for the G3 group in comparison with the G0 group ranged from 1.24 to 3.46 for the 13 significantly increased metabolites and was 0.17 for 8,9-diHETrE. The representative metabolites with large fold changes in their levels are shown in Figure 2 .
TA B L E 3 Lipid metabolites with significant P values between groups of multiple myeloma patients with 4 ordered grades (G0-G3) of peripheral neuropathy due to treatment with bortezomib and low-dose dexamethasone (BiPN) 
Class Subclass Metabolites
Fatty acid composition of GPL P value
Median fold change (G1/G0)
Median fold change (G2/G0)
Median fold change (G3/G0)
GPL
| D ISCUSS I ON
Our study is the first comprehensive lipidomics analysis of pretreatment sera in order to explore which biomarkers could predict an optimal response to BTZ-based chemotherapy and BiPN. The levels of 10 lipid metabolites, 2 PCs, 5 ether PEs, 1 SM, and 2 ChEs in the pretreatment sera were increased progressively from the nonresponders, across the minor/partial responders, to the good responders (P < .005). To identify potential confounding factors influencing lipid metabolite levels in the blood for our biomarker exploration study, we examined the association between patients' backgrounds and their response to Bd therapy. There were no differences in the total cholesterol and triglyceride levels and hemoglobin concentrations between responders and nonresponders, whereas serum albumin levels showed a trend towards decrease (P = .0095, not significant) in nonresponders. Serum albumin is the carrier of fatty acids in the blood and reflects the patients' nutritional status, suggesting that in nonresponders both the nutritional status was inferior, and fatty acids might not be supplied in sufficient amount for the biosynthesis of GPLs and NLs. Then, to assess the influence of the different nutritional status between responders and nonresponders on the lipid biomarker exploration for Bd response, we examined the association between serum albumin and the levels of 10 lipid biomarker candidates. There was no significant correlation (P > .005, Spearman rank correlation test) between the specific lipid levels and the serum albumin, with the exception of PE(38:7e) (P = .0045) and SM(39:1) (P = .0014),
indicating that at least 8 biomarker candidates are associated with the Bd response and not with the patients' nutritional status. In addition to serum albumin levels, the BMI tended to be lower in nonresponders than in responders (P = .0296). As the BMI has been extensively correlated with metabolite levels such as lipoprotein cholesterols and triacylglycerols, 15 we cannot rule out the possibility that our findings were confounded by the BMI. However, the levels of these 10 lipids and BMI were not significantly correlated (P > .005, Spearman rank correlation test). Therefore, the lower levels of both albumin and BMI in nonresponders are unlikely to be a confounding factor for the decreased levels of these lipid species, although a careful validation taking into account patients' backgrounds is needed for a few metabolites.
Several reports have indicated that MM pathophysiology is supported by a strong interaction between clonal plasma cells and the surrounding bone marrow microenvironment. Marrow fat might participate in the lipid metabolism by clearing and storing circulating triglycerides, thereby providing a localized energy reservoir for osteogenesis. 16 Ether PE species appear to be potential biomarker candidates for predicting BD responsiveness, whereas ether PC spe- (P = .0055), and LPC(20:5) (P = .0087), showed borderline significant association. These results implicate phospholipase A2, which hydrolyzes phospholipids to produce lysophospholipids and a free fatty acid, in BiPN. 19 Phospholipase A2 provides precursors for eicosanoid generation, when the cleaved fatty acid is arachidonic acid, or for PAF formation from ether-type PC, playing key roles in the inflammatory responses. Furthermore, LPC as a bioactive lipid, has been shown to enhance intracellular Ca 2+ levels in many cell types, resulting in LPC-induced demyelination and axonal degeneration. 20, 21 In addition, LPCs are known to cause neuropathic pain through the increase of neuronal nitric oxide synthase in the dorsal root ganglion. 22 It was notable that differences in the levels of cytochrome 23 Transient receptor potential vanilloid-4 has an important role through its expression in sensory neurons for the mechanotransduction of peripheral neuropathy-associated pain. 24 Furthermore, TRPV4
inhibition prevents paclitaxel-induced neurotoxicity in preclinical models. 25 In contrast, epoxides from arachidonic acid and eicos- In conclusion, a comprehensive lipidomic study using pretreat- Masaki Ri https://orcid.org/0000-0002-9617-486X Shinsuke Iida https://orcid.org/0000-0002-4951-960X
